Startseite › Endometriumkarzinom › Illinois › Chicago
Klinische Studien zu Endometriumkarzinom in Chicago, IL
25 Studien zu Endometriumkarzinom suchen Teilnehmer an Standorten in und um Chicago (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Teilnehmer gesuchtPhase 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- und 3 weitere
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Teilnehmer gesuchtPhase 1
- University of Chicago Comprehensive Cancer Center, Chicago
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Teilnehmer gesuchtPhase 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 2
- University of Illinois Cancer Center, Chicago
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Teilnehmer gesuchtBeobachtungsstudie
- University of Chicago, Chicago
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Research Site, Chicago
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Teilnehmer gesuchtPhase 1/2
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Teilnehmer gesuchtPhase 2
- Northwestern University, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Teilnehmer gesuchtPhase 1
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Teilnehmer gesuchtPhase 3
- University of Chicago Medical Center ( Site 5002), Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Chicago Medical Center, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Teilnehmer gesuchtPhase 1/2
- Lurie Children's Hospital-Chicago, Chicago
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Teilnehmer gesuchtPhase 2
- Northwestern Medicine, Chicago
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Teilnehmer gesuchtPhase 1/2
- University of Chicago Medical Center, Chicago
A Study of PHST001 in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Chicago Medical Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Teilnehmer gesuchtPhase 3
- Research Site, Chicago
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Northwestern University, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Teilnehmer gesuchtPhase 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Teilnehmer gesuchtPhase 1/2
- Northwestern Memorial Hospital, Chicago
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Teilnehmer gesucht
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Teilnehmer gesuchtPhase 1/2
- University of Chicago Medical Center, Chicago
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Teilnehmer gesucht
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Chicago
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Endometriumkarzinom-Studien in anderen Städten
- Houston, TX68 Studien
- New York City, NY52 Studien
- Boston, MA50 Studien
- Arlington, VA39 Studien
- Nashville, TN38 Studien
- Los Angeles, CA34 Studien
- St. Louis, MO29 Studien
- Philadelphia, PA28 Studien
- San Antonio, TX27 Studien
- Columbus, OH25 Studien
- Queens, NY25 Studien
- Oklahoma City, OK25 Studien
Weitere Studien in Chicago
- Nichtkleinzelliges Lungenkarzinom61 Studien
- Brustkrebs58 Studien
- Krebs (alle Arten)51 Studien
- Metastasierender Krebs45 Studien
- Prostatakrebs45 Studien
- Adipositas41 Studien
- Lungenkrebs41 Studien
- Eierstockkrebs36 Studien
- Schlaganfall34 Studien
- Kolorektales Karzinom33 Studien
- Herzinsuffizienz31 Studien
- Übergewicht28 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.